The scientists say when activated, one protein, called the short form, stops glioblastoma cells from replicating their DNA, and the other, called the long form, prevents cell division if the DNA has already been replicated, explains Rebecca Riggins, PhD, assistant professor of oncology at Georgetown Lombardi. The study was posted online Dec. …
source : http://www.sciencedaily.com/releases/2014/06/140629142035.htm
source : http://www.sciencedaily.com/releases/2014/02/140211174757.htm
source : http://www.sciencedaily.com/releases/2014/01/140121164741.htm
The landscape of genetic testing has broadened to include a range of diseases, and demand for testing and counseling has greatly increased because of direct-to-consumer marketing, says the study’s lead investigator, Marc Schwartz, PhD, co-leader of Georgetown Lombardi’s Cancer Prevention and Control Program. "It’s important that all people interested in testing have access to thorough information so they can consider the implications of test results and interpret them in the context of family history," says Schwartz, who is also co-leader of the Fisher Center for Familial Cancer Research at Georgetown. "Counseling on the phone reduces costs and expands genetic counseling and testing access to rural areas, where counseling isn’t always available." While this study was conducted with women considering testing for mutations in the breast or ovarian cancer genes BRCA1 and/or BRCA2, the findings "may extend to genetic counseling for other hereditary cancers and complex conditions in adults such as heart disease," says co-author Beth N. …
The study, published in Oncotarget, was led by investigators at Georgetown University Medical Center (GUMC), and included collaborators from Harvard and Columbia Universities, Mayo Clinic and Queen’s University in Belfast, Northern Ireland. "Our findings suggest that cadherin-11 is important for cancer progression as well as rheumatoid arthritis — for reasons we do not fully understand. …
The investigators identified STAG2 as one of the most commonly mutated genes in bladder cancer, particularly in tumors that do not spread. The finding suggests that checking the status of the gene may help identify patients who might do unusually well following cancer treatment, says the study’s senior investigator, cancer geneticist Todd Waldman, MD, PhD, a professor of oncology at Georgetown Lombardi. "Most bladder cancers are superficial tumors that have not spread to other parts of the body, and can therefore be easily treated and cured. However, a small fraction of these superficial tumors will recur and metastasize even after treatment," he says. …
CUSTOM is the first completed prospective clinical trial that used genetic analysis alone to assign cancer treatment for patients with one of three different cancers. "We expected it would take five years to enroll 600 patients into CUSTOM. But in less than two years, 668 patients were recruited," says the study’s lead investigator, Giuseppe Giaccone, MD, PhD, associate director for clinical research at Georgetown Lombardi Comprehensive Cancer Center. "This was a surprise to all of us, especially since patients with advanced cancer who already had biopsies needed to undergo an additional biopsy for the study. …
A drug currently being used to treat leukemia has been found to help halt the production of toxic proteins in the brain linked to Alzheimer’s disease, Parkinson’s disease and various forms of dementia. Researchers from Georgetown University successfully used small doses of the drug nilotinib, used to treat chronic myelogenous leukemia (CML), to eliminate abnormal protein build-up in the brains of mice. The scientists targeted the alpha-Synuclein and tau proteins, which have been previously implicated in the development of Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Huntington’s disease, Lewy body dementia and other neurodegenerative conditions. …
A drug currently being used to treat leukemia has been found to help halt the production of toxic proteins in the brain linked to Alzheimer’s disease, Parkinson’s disease and various forms of dementia. Researchers from Georgetown University successfully used small doses of the drug nilotinib, used to treat chronic myelogenous leukemia (CML), to eliminate abnormal protein build-up in the brains of mice. The scientists targeted the alpha-Synuclein and tau proteins, which have been previously implicated in the development of Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Huntington’s disease, Lewy body dementia and other neurodegenerative conditions. …